Bevacizumab	0	11	B-Drug_or_compound
and	12	15	O
irinotecan	16	26	B-Drug_or_compound
therapy	27	34	O
in	35	37	O
glioblastoma	38	50	B-Pathological_formation
multiforme	51	61	I-Pathological_formation
:	61	62	O
a	63	64	O
series	65	71	O
of	72	74	O
13	75	77	O
cases	78	83	O
.	83	84	O

OBJECT	86	92	O
:	92	93	O
Endothelial	94	105	B-Cell
proliferation	106	119	O
has	120	123	O
been	124	128	O
recognized	129	139	O
as	140	142	O
a	143	144	O
marker	145	151	O
of	152	154	O
high	155	159	O
-	159	160	O
grade	160	165	O
or	166	168	O
aggressive	169	179	O
glioma	180	186	B-Pathological_formation
.	186	187	O

Bevacizumab	188	199	B-Drug_or_compound
is	200	202	O
a	203	204	O
humanized	205	214	O
immunoglobulin	215	229	B-Gene_or_gene_product
G1	230	232	I-Gene_or_gene_product
monoclonal	233	243	O
antibody	244	252	O
to	253	255	O
vascular	256	264	B-Gene_or_gene_product
endothelial	265	276	I-Gene_or_gene_product
growth	277	283	I-Gene_or_gene_product
factor	284	290	I-Gene_or_gene_product
that	291	295	O
has	296	299	O
been	300	304	O
shown	305	310	O
to	311	313	O
have	314	318	O
activity	319	327	O
in	328	330	O
malignant	331	340	O
gliomas	341	348	B-Pathological_formation
when	349	353	O
combined	354	362	O
with	363	367	O
irinotecan	368	378	B-Drug_or_compound
.	378	379	O

The	380	383	O
authors	384	391	O
report	392	398	O
on	399	401	O
a	402	403	O
case	404	408	O
series	409	415	O
of	416	418	O
13	419	421	O
patients	422	430	B-Organism
with	431	435	O
recurrent	436	445	O
heavily	446	453	O
pretreated	454	464	O
malignant	465	474	O
glioma	475	481	B-Pathological_formation
that	482	486	O
was	487	490	O
treated	491	498	O
with	499	503	O
the	504	507	O
combination	508	519	O
of	520	522	O
bevacizumab	523	534	B-Drug_or_compound
and	535	538	O
irinotecan	539	549	B-Drug_or_compound
.	549	550	O

METHODS	551	558	O
:	558	559	O
Standard	560	568	O
therapy	569	576	O
with	577	581	O
primary	582	589	O
resection	590	599	O
followed	600	608	O
by	609	611	O
adjuvant	612	620	O
chemotherapy	621	633	O
and	634	637	O
radiation	638	647	O
had	648	651	O
failed	652	658	O
in	659	661	O
all	662	665	O
patients	666	674	B-Organism
.	674	675	O

The	676	679	O
median	680	686	O
number	687	693	O
of	694	696	O
therapies	697	706	O
applied	707	714	O
,	714	715	O
including	716	725	O
initial	726	733	O
surgery	734	741	O
,	741	742	O
was	743	746	O
5	747	748	O
(	749	750	O
range	750	755	O
3	756	757	O
-	757	758	O
7	758	759	O
therapies	760	769	O
)	769	770	O
.	770	771	O

Nine	772	776	O
patients	777	785	B-Organism
were	786	790	O
started	791	798	O
on	799	801	O
bevacizumab	802	813	B-Drug_or_compound
at	814	816	O
a	817	818	O
dose	819	823	O
of	824	826	O
5	827	828	O
mg	829	831	O
/	831	832	O
m2	832	834	O
every	835	840	O
2	841	842	O
weeks	843	848	O
.	848	849	O

Four	850	854	O
patients	855	863	B-Organism
received	864	872	O
bevacizumab	873	884	B-Drug_or_compound
at	885	887	O
a	888	889	O
dose	890	894	O
of	895	897	O
10	898	900	O
mg	901	903	O
/	903	904	O
m2	904	906	O
;	906	907	O
irinotecan	908	918	B-Drug_or_compound
was	919	922	O
given	923	928	O
at	929	931	O
a	932	933	O
dose	934	938	O
of	939	941	O
125	942	945	O
mg	946	948	O
/	948	949	O
m2	949	951	O
every	952	957	O
week	958	962	O
for	963	966	O
3	967	968	O
weeks	969	974	O
.	974	975	O

RESULTS	976	983	O
:	983	984	O
Of	985	987	O
the	988	991	O
13	992	994	O
treated	995	1002	O
patients	1003	1011	B-Organism
,	1011	1012	O
10	1013	1015	O
(	1016	1017	O
77	1017	1019	O
%	1019	1020	O
)	1020	1021	O
had	1022	1025	O
a	1026	1027	O
radiologically	1028	1042	O
demonstrated	1043	1055	O
partial	1056	1063	O
response	1064	1072	O
and	1073	1076	O
3	1077	1078	O
(	1079	1080	O
23	1080	1082	O
%	1082	1083	O
)	1083	1084	O
had	1085	1088	O
stable	1089	1095	O
disease	1096	1103	O
.	1103	1104	O

Six	1105	1108	O
patients	1109	1117	B-Organism
(	1118	1119	O
46	1119	1121	O
%	1121	1122	O
)	1122	1123	O
had	1124	1127	O
a	1128	1129	O
clinical	1130	1138	O
response	1139	1147	O
.	1147	1148	O

The	1149	1152	O
median	1153	1159	O
time	1160	1164	O
to	1165	1167	O
disease	1168	1175	O
progression	1176	1187	O
while	1188	1193	O
on	1194	1196	O
treatment	1197	1206	O
was	1207	1210	O
24	1211	1213	O
weeks	1214	1219	O
.	1219	1220	O

The	1221	1224	O
median	1225	1231	O
overall	1232	1239	O
survival	1240	1248	O
was	1249	1252	O
27	1253	1255	O
weeks	1256	1261	O
.	1261	1262	O

The	1263	1266	O
disease	1267	1274	O
progressed	1275	1285	O
in	1286	1288	O
8	1289	1290	O
patients	1291	1299	B-Organism
,	1299	1300	O
despite	1301	1308	O
an	1309	1311	O
initial	1312	1319	O
response	1320	1328	O
.	1328	1329	O

Five	1330	1334	O
patients	1335	1343	B-Organism
are	1344	1347	O
still	1348	1353	O
responding	1354	1364	O
to	1365	1367	O
therapy	1368	1375	O
.	1375	1376	O

Six	1377	1380	O
of	1381	1383	O
the	1384	1387	O
8	1388	1389	O
patients	1390	1398	B-Organism
whose	1399	1404	O
disease	1405	1412	O
progressed	1413	1423	O
have	1424	1428	O
died	1429	1433	O
.	1433	1434	O

Bevacizumab	1435	1446	B-Drug_or_compound
was	1447	1450	O
discontinued	1451	1463	O
in	1464	1466	O
2	1467	1468	O
patients	1469	1477	B-Organism
because	1478	1485	O
of	1486	1488	O
nonfatal	1489	1497	O
intracranial	1498	1510	B-Immaterial_anatomical_entity
bleeding	1511	1519	O
.	1519	1520	O

CONCLUSIONS	1521	1532	O
:	1532	1533	O
The	1534	1537	O
combination	1538	1549	O
of	1550	1552	O
bevacizumab	1553	1564	B-Drug_or_compound
and	1565	1568	O
irinotecan	1569	1579	B-Drug_or_compound
is	1580	1582	O
safe	1583	1587	O
and	1588	1591	O
has	1592	1595	O
excellent	1596	1605	O
activity	1606	1614	O
even	1615	1619	O
in	1620	1622	O
this	1623	1627	O
relapsed	1628	1636	O
,	1636	1637	O
heavily	1638	1645	O
pretreated	1646	1656	O
population	1657	1667	O
of	1668	1670	O
patients	1671	1679	B-Organism
with	1680	1684	O
high	1685	1689	O
-	1689	1690	O
grade	1690	1695	O
malignant	1696	1705	O
glioma	1706	1712	B-Pathological_formation
,	1712	1713	O
most	1714	1718	O
of	1719	1721	O
whom	1722	1726	O
would	1727	1732	O
not	1733	1736	O
be	1737	1739	O
candidates	1740	1750	O
for	1751	1754	O
clinical	1755	1763	O
trials	1764	1770	O
.	1770	1771	O

